TNBI Tanke Biosciences Corp
Grain Mill Products · OTC · SEC CIK 1452011 · Fiscal year ends 12/31
Financial factors as of 2013-09-30 (2013Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.5%
TTM net income YoY-164.1%
TTM EPS YoY-165.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin32.3%
Operating margin-0.2%
Net margin-7.1%
FCF margin-27.3%
EBITDA margin2.1%
Returns
ROE-10.2%
ROA-5.7%
ROIC (approx.)-0.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets45.5%
Debt / equity0.12x
Current ratio1.61x
Interest coverage-0.10x
Cash quality & payout
Operating cash flow / net income2.30x
Accruals ratio7.4%
Payout ratio—
Capex / revenue10.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2013Q32013-09-30 | 2013Q22013-06-30 | 2013Q12013-03-31 | 2012Q4*2012-12-31 | 2012Q32012-09-30 | 2012Q22012-06-30 | 2012Q12012-03-31 | 2011Q4*2011-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.04M | $5.58M | $4.66M | $6.68M | $9.91M | $7.43M | $4.54M | $6.65M |
| Cost of revenue | $4.35M | $3.75M | $2.99M | $4.45M | $6.52M | $4.69M | $2.95M | $4.33M |
| Gross profit | $1.69M | $1.82M | $1.67M | $2.23M | $3.39M | $2.74M | $1.59M | $2.33M |
| R&D expense | — | — | — | $182,243 | — | — | — | — |
| SG&A expense | $1.36M | $997,469 | $981,590 | $776,343 | $574,092 | $680,232 | $541,004 | $616,485 |
| Operating income | -$530,338 | $149,690 | -$39,893 | $363,273 | $2.18M | $1.50M | $488,508 | $1.02M |
| Interest expense | -$46,575 | $39,376 | $215,059 | $387,496 | $316,422 | $368,782 | $373,087 | -$135,661 |
| Pretax income | -$339,851 | $169,194 | -$646,745 | -$620,189 | $1.19M | $585,916 | -$554,281 | $2.16M |
| Income tax | -$26,907 | $53,512 | $32,099 | $178,886 | $222,513 | $313,502 | $116,696 | $175,816 |
| Net income | -$302,084 | $118,164 | -$676,329 | -$780,316 | $968,632 | $272,414 | -$670,977 | $1.99M |
| EBITDA | -$463,001 | $201,929 | $139,993 | $595,436 | $2.20M | $1.51M | $612,310 | $1.29M |
| EPS (basic) | -0.02 | 0.01 | -0.05 | — | 0.07 | 0.02 | -0.05 | — |
| EPS (diluted) | -0.02 | 0.01 | -0.05 | — | 0.07 | 0.02 | -0.05 | — |
| Weighted avg. shares (diluted) | 13.32M | 13.32M | 13.32M | — | 13.32M | 13.32M | 13.32M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.05M | $4.72M | $5.59M | $6.17M | $11.04M | $10.03M | $7.64M | $7.70M |
| Receivables | $2.76M | $2.38M | $1.85M | $1.99M | $2.28M | $1.82M | $1.72M | $1.92M |
| Inventory | $1.65M | $2.08M | $1.40M | $1.41M | $1.64M | $1.26M | $1.36M | $1.19M |
| Current assets | $19.70M | $21.92M | $21.74M | $22.37M | $22.20M | $20.65M | $18.37M | $18.91M |
| PP&E, net | $6.34M | $5.26M | $5.16M | $4.81M | $4.92M | $4.87M | $4.88M | $4.77M |
| Intangibles | $1.15M | $1.19M | $1.20M | $1.24M | $1.27M | $1.32M | $844,573 | $838,089 |
| Total assets | $28.81M | $29.47M | $28.66M | $28.85M | $28.84M | $27.29M | $24.45M | $24.89M |
| Current liabilities | $12.24M | $12.70M | $11.79M | $12.10M | $11.16M | $9.77M | $8.82M | $3.55M |
| Short-term debt | $1.14M | $1.29M | $796,950 | $1.27M | $1.34M | $793,817 | $1.11M | $785,456 |
| Long-term debt | $732,649 | $808,848 | $1.43M | $792,567 | $948,391 | $1.59M | $0 | $628,365 |
| Total debt | $1.87M | $2.10M | $2.23M | $2.06M | $2.29M | $2.38M | $1.11M | $1.41M |
| Total liabilities | $13.10M | $13.59M | $13.28M | $12.93M | $12.31M | $11.62M | $9.16M | $9.03M |
| Shareholders' equity | $15.56M | $15.71M | $15.21M | $15.75M | $16.53M | $15.67M | $15.30M | $15.85M |
| Net debt | -$3.18M | -$2.62M | -$3.35M | -$4.11M | -$8.75M | -$7.65M | -$6.53M | -$6.29M |
| Shares outstanding | 13.32M | 13.32M | 13.32M | 13.32M | 13.32M | 13.32M | 13.32M | 13.32M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.61M | -$134,582 | -$101,190 | -$5.16M | $1.55M | $1.77M | $508,675 | $731,202 |
| Capital expenditure | $1.07M | $613,496 | $746,033 | $56,439 | $411,576 | $194,713 | $193,633 | $224,386 |
| Free cash flow | $538,076 | -$748,078 | -$847,223 | -$5.21M | $1.14M | $1.57M | $315,042 | $506,816 |
| Investing cash flow | -$1.08M | -$645,210 | -$746,033 | $257,973 | -$394,306 | -$866,457 | -$380,145 | -$2.11M |
| Financing cash flow | -$241,200 | -$159,200 | $230,199 | $75,532 | -$44,933 | $1.40M | -$304,738 | -$3.07M |
| Depreciation & amortization | $67,337 | $52,239 | $179,886 | $232,163 | $16,642 | $14,763 | $123,802 | $274,450 |
| Stock-based compensation | — | — | — | — | — | — | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.